In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.
about
Fourth Generation of Next-Generation Sequencing Technologies: Promise and ConsequencesDevelopment of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE SamplesOverview on Clinical Relevance of Intra-Tumor Heterogeneity.Quantification and localization of oncogenic receptor tyrosine kinase variant transcripts using molecular inversion probes.
P2860
In situ sequencing identifies TMPRSS2-ERG fusion transcripts, somatic point mutations and gene expression levels in prostate cancers.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
In situ sequencing identifies ...... on levels in prostate cancers.
@en
In situ sequencing identifies ...... on levels in prostate cancers.
@nl
type
label
In situ sequencing identifies ...... on levels in prostate cancers.
@en
In situ sequencing identifies ...... on levels in prostate cancers.
@nl
prefLabel
In situ sequencing identifies ...... on levels in prostate cancers.
@en
In situ sequencing identifies ...... on levels in prostate cancers.
@nl
P2093
P2860
P356
P1476
In situ sequencing identifies ...... ion levels in prostate cancers
@en
P2093
Anders Bergh
Marco Mignardi
Mats Nilsson
Sara Kiflemariam
Tobias Sjöblom
P2860
P304
P356
10.1002/PATH.4392
P577
2014-08-04T00:00:00Z